{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:55:00Z","timestamp":1776207300145,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Fetal Alcohol Spectrum Disorder (FASD) is a neurodevelopmental condition resulting from pre-natal alcohol exposure. In Canada, an estimated 1.4-4% of newborns are affected by FASD. FASD is often associated with behavioural comorbidities and many individuals require psychotropic medication. However, to date there are no FASD specific guidelines for prescribing medication. Recently, Mela and colleagues described four behavioural symptom clusters commonly seen in FASD with suggested pharmacologic treatment for each cluster within an algorithm. The primary objective was to compare the proposed treatment algorithm retrospectively to actual treatment in a real-world FASD pediatric practice. The secondary objective was to refine the description of symptom clusters which will be targeted with treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We collected the diagnostic and medication history from all patient visits of a Regina Developmental Pediatrician who specializes in FASD diagnosis and medication treatment. Three hundred fifty-four FASD patients were identified between 2005 to 2020. The medications that would be predicted from the algorithm were compared to the real-world historical data. A positive case was defined as all algorithm-predicted medications matching the historical data; a negative case had one or more medications failing to match.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 354 patients, 36 were removed for insufficient information. Of the remaining 318 cases, 172 (54.1%) were positive compared to 146 (45.9%) negatives. In single prescription cases (<jats:italic>n<\/jats:italic>=147), the incidence of positives was 67.3%; in multi-prescriptions (<jats:italic>n<\/jats:italic>=72) it was 27.8%; and in cases where no prescription was needed (<jats:italic>n<\/jats:italic>=99), the positive incidence was 53.5%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The prescription algorithm is promising but requires further refinement to accommodate the range of presentations in children with FASD. With respect to unclassified symptoms, we propose the following: sleep onset difficulty as <jats:italic>hyperarousal<\/jats:italic>; gender dysphoria and obsessive compulsive disorder as <jats:italic>cognitive inflexibility<\/jats:italic>; grief as <jats:italic>emotional regulation<\/jats:italic>; and autism spectrum disorder as <jats:italic>hyperactive\/neurocognitive<\/jats:italic>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-021-02986-5","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T09:04:49Z","timestamp":1637053489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Utilization of psychotropic medications in children with FASD: a retrospective review"],"prefix":"10.1186","volume":"21","author":[{"given":"Michael-Roy R.","family":"Durr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Petryk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansfield","family":"Mela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"DesRoches","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mackenzie","family":"Wekerle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjida","family":"Newaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"2986_CR1","unstructured":"Popova S, Lange S, Chudley AE, Reynolds JN, J\u00fcrgen R, May PA, et al. World Health Organization International Study on the Prevalence of Fetal Alcohol Spectrum Disorder (FASD) Canadian Component [Internet]. Institute for Mental Health Policy Research, Centre for Addiction and Mental Health. World Health Organisation; 2018. Available from: https:\/\/canfasd.ca\/wp-content\/uploads\/2018\/05\/2018-Popova-WHO-FASD-Prevalance-Report.pdf"},{"key":"2986_CR2","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders [Internet]. American Psychiatric Association; 2013. https:\/\/doi.org\/10.1176\/appi.books.9780890425596","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"1","key":"2986_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejmg.2016.10.005","volume":"60","author":"CLM Petrenko","year":"2017","unstructured":"Petrenko CLM, Alto ME. Interventions in fetal alcohol spectrum disorders: an international perspective. Eur J Med Genet. 2017;60(1):79\u201391 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769721216303937.","journal-title":"Eur J Med Genet"},{"issue":"12","key":"2986_CR4","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1111\/acer.14490","volume":"44","author":"K Flannigan","year":"2020","unstructured":"Flannigan K, Coons-Harding KD, Anderson T, Wolfson L, Campbell A, Mela M, et al. A systematic review of interventions to improve mental health and substance use outcomes for individuals with prenatal alcohol exposure and fetal alcohol spectrum disorder. Alcohol Clin Exp Res. 2020;44(12):2401\u201330.","journal-title":"Alcohol Clin Exp Res."},{"issue":"1","key":"2986_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2431-9-35","volume":"9","author":"E Peadon","year":"2009","unstructured":"Peadon E, Rhys-Jones B, Bower C, Elliott EJ. Systematic review of interventions for children with fetal alcohol spectrum disorders. BMC Pediatr. 2009;9(1):35. https:\/\/doi.org\/10.1186\/1471-2431-9-35.","journal-title":"BMC Pediatr"},{"issue":"4","key":"2986_CR6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1080\/24750573.2018.1458429","volume":"28","author":"M Mela","year":"2018","unstructured":"Mela M, Okpalauwaekwe U, Anderson T, Eng J, Nomani S, Ahmed A, et al. The utility of psychotropic drugs on patients with Fetal Alcohol Spectrum Disorder (FASD): a systematic review. Psychiatry Clin Psychopharmacol. 2018;28(4):436\u201345. https:\/\/doi.org\/10.1080\/24750573.2018.1458429.","journal-title":"Psychiatry Clin Psychopharmacol"},{"key":"2986_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/B978-0-12-800016-8.00006-4","volume-title":"The Science and Ethics of Antipsychotic Use in Children [Internet]","author":"O Ipsiroglu","year":"2015","unstructured":"Ipsiroglu O, Berger M, Lin T, Elbe D, Stockler S, Carleton B. Pathways to overmedication and polypharmacy. In:  The Science and Ethics of Antipsychotic Use in Children [Internet]: Elsevier; 2015. p. 125\u201348. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128000168000064."},{"issue":"2","key":"2986_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/YCO.0000000000000233","volume":"29","author":"NY Ji","year":"2016","unstructured":"Ji NY, Findling RL. Pharmacotherapy for mental health problems in people with intellectual disability. Curr Opin Psychiatry. 2016;29(2):103\u201325 Available from: http:\/\/journals.lww.com\/00001504-201603000-00004.","journal-title":"Curr Opin Psychiatry."},{"issue":"2","key":"2986_CR9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1542\/peds.2014-2171","volume":"135","author":"IJ Chasnoff","year":"2015","unstructured":"Chasnoff IJ, Wells AM, King L. Misdiagnosis and missed diagnoses in foster and adopted children with prenatal alcohol exposure. Pediatrics. 2015;135(2):264\u201370. https:\/\/doi.org\/10.1542\/peds.2014-2171.","journal-title":"Pediatrics."},{"issue":"5","key":"2986_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3109\/10673229.2011.614483","volume":"19","author":"LA Bajor","year":"2011","unstructured":"Bajor LA, Ticlea AN, Osser DN. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on posttraumatic stress disorder. Harv Rev Psychiatry. 2011;19(5):240\u201358 Available from: http:\/\/journals.lww.com\/00023727-201109200-00003.","journal-title":"Harv Rev Psychiatry."},{"issue":"3","key":"2986_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40474-015-0053-7","volume":"2","author":"EM Moore","year":"2015","unstructured":"Moore EM, Riley EP. What happens when children with fetal alcohol spectrum disorders become adults? Curr Dev Disord Reports. 2015;2(3):219\u201327. https:\/\/doi.org\/10.1007\/s40474-015-0053-7.","journal-title":"Curr Dev Disord Reports"},{"issue":"1","key":"2986_CR12","first-page":"E59","volume":"22","author":"J Ozsarfati","year":"2015","unstructured":"Ozsarfati J, Koren G. Medications used in the treatment of disruptive behavior in children with fasd - a guide. J Popul Ther Clin Pharmacol. 2015;22(1):E59\u201367.","journal-title":"J Popul Ther Clin Pharmacol."},{"issue":"4","key":"2986_CR13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/15622970802465807","volume":"9","author":"B Bandelow","year":"2008","unstructured":"Bandelow B, Zohar J, Hollander E, Kasper S, M\u00f6ller HJ, Allgulander C, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - First revision. World J Biol Psychiatry. 2008;9(4):248\u2013312.","journal-title":"World J Biol Psychiatry."},{"issue":"3","key":"2986_CR14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.15586\/jptcp.v27i3.681","volume":"27","author":"M Mela","year":"2020","unstructured":"Mela M, Hanlon-Dearman A, Ahmed AG, Rich SD, Densmore R, Reid D, et al. Treatment algorithm for the use of psychopharmacological agents in individuals prenatally exposed to alcohol and\/or with diagnosis of fetal alcohol spectrum disorder (FASD). J Popul Ther Clin Pharmacol. 2020;27(3):e1\u201313 Available from: https:\/\/jptcp.com\/index.php\/jptcp\/article\/view\/681.","journal-title":"J Popul Ther Clin Pharmacol."},{"issue":"3","key":"2986_CR15","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","volume":"22","author":"ML McHugh","year":"2012","unstructured":"McHugh ML. Interrater reliability: the kappa statistic. Biochem Medica. 2012;22(3):276\u201382 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23092060.","journal-title":"Biochem Medica"},{"issue":"4","key":"2986_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000501647","volume":"88","author":"B Thombs","year":"2019","unstructured":"Thombs B, Turner KA, Shrier I. Defining and evaluating overdiagnosis in mental health: a meta-research review. Psychother Psychosom. 2019;88(4):193\u2013202 Available from: https:\/\/www.karger.com\/Article\/FullText\/501647.","journal-title":"Psychother Psychosom."},{"issue":"11","key":"2986_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3949\/ccjm.84a.15051","volume":"84","author":"MJ Manos","year":"2017","unstructured":"Manos MJ, Giuliano K, Geyer E. ADHD: overdiagnosed and overtreated, or misdiagnosed and mistreated? Cleve Clin J Med. 2017;84(11):873\u201380. https:\/\/doi.org\/10.3949\/ccjm.84a.15051.","journal-title":"Cleve Clin J Med"},{"issue":"5","key":"2986_CR18","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/mp.2017.75","volume":"23","author":"EA Demetriou","year":"2018","unstructured":"Demetriou EA, Lampit A, Quintana DS, Naismith SL, Song YJC, Pye JE, et al. Autism spectrum disorders: a meta-analysis of executive function. Mol Psychiatry [Internet]. 2018;23(5):1198\u2013204 Available from: http:\/\/www.nature.com\/articles\/mp201775.","journal-title":"Mol Psychiatry [Internet]."},{"key":"2986_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3389\/fpsyt.2019.00753\/full","volume":"10","author":"EA Demetriou","year":"2019","unstructured":"Demetriou EA, DeMayo MM, Guastella AJ. Executive function in autism spectrum disorder: history, theoretical models, empirical findings, and potential as an endophenotype. Front Psychiatry. 2019;10:753. https:\/\/doi.org\/10.3389\/fpsyt.2019.00753\/full.","journal-title":"Front Psychiatry"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-021-02986-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-021-02986-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-021-02986-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T09:05:44Z","timestamp":1637053544000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-021-02986-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2986"],"URL":"https:\/\/doi.org\/10.1186\/s12887-021-02986-5","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]},"assertion":[{"value":"30 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received ethics approval (REB-20-45) and operational approval (OA-SHA-2-45) from the Saskatchewan Health Authority research ethics board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Mansfield Mela was the lead author of the FASD algorithm. To mitigate the potential bias, he was not involved in the collection or analysis of the datasets.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"512"}}